Serious arterial thromboembolic events (sATE) in patients (pts) with metastatic colorectal cancer (mCRC) treated with bevacizurnab (BV): results from the BRITE registry

被引：0
|
作者：
Sing, A. [1 ]
Sugrue, M. [1 ]
Chiruvolu, R. [1 ]
Yi, J. [1 ]
Purdie, D. [1 ]
Dong, W. [1 ]
Grothey, A. [2 ]
Kozloff, M. [3 ]
机构：
[1] Genentech Inc, San Francisco, CA USA
[2] Mayo Clin, Rochester, MN USA
[3] Univ Chicago, Ingalls Hosp, Harvey, KS USA
来源：
EJC SUPPLEMENTS | 2007年 / 5卷 / 04期
关键词：
D O I：
10.1016/S1359-6349(07)70973-4
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3045
引用
收藏
页码：249 / 249
页数：1
相关论文
共 50 条
  • [21] EGFL7 polymorphism to predict tumor response in metastatic colorectal cancer (mCRC) patients (pts) treated with FOLFIRI and bevacizumab (BV)
    Li, Joseph Ethan
    Zhang, Wu
    Loupakis, Fotios
    Yang, Dongyun
    Wakatsuki, Takeru
    Ning, Yan
    Stintzing, Sebastian
    El-Khoueiry, Rita Elie
    Volz, Nico Benjamin
    Marmorino, Federica
    Schirripa, Marta
    Salvatore, Lisa
    Antoniotti, Carlotta
    Cremolini, Chiara
    Lenz, Heinz-Josef
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [22] Phase Ib study of dulanermin combined with FOLFIRI (with or without bevacizumab [BV]) in previously treated patients (Pts) with metastatic colorectal cancer (mCRC)
    Kasubhai, Saifuddin M.
    Bendell, Johanna C.
    Kozloff, Mark
    Kapp, Amy V.
    Ashkenazi, Avi
    Royer-Joo, Stephanie
    Portera, Chia C.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [23] Capecitabine plus irinotecan plus bevacizurnab as first-line therapy for patients (pts) with metastatic colorectal cancer (MCRC): preliminary phase II study results
    Beslija, S.
    Banjin, M.
    Jungic, S.
    Obralic, N.
    Kecman-Malcic, G.
    Rakita, I.
    Salkic, B.
    Pasic, A.
    Tinjic, L.
    Ajanovic, E.
    EJC SUPPLEMENTS, 2007, 5 (04): : 256 - 257
  • [24] Molecular characterization of metastatic colorectal cancer (mCRC) in patients (pts) treated with cetuximab and pembrolizumab.
    Fountzilas, Christos
    Rosario, Spencer
    Withers, Henry G.
    Mukherjee, Sarbajit
    Bajor, David L.
    Saltzman, Joel N.
    Wang, Chong
    Attwood, Kristopher
    Knudsen, Erik S.
    Witkiewicz, Agnieszka K.
    Iyer, Renuka V.
    Boland, Patrick M.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 178 - 178
  • [25] Irinotecan (Iri) and buparlisib (B) in previously treated patients (pts) with metastatic colorectal cancer (mCRC).
    Baranda, Joaquina Celebre
    Reed, Greg
    Williamson, Stephen K.
    Perez, Raymond P.
    Stoltz, Maxine L.
    Mackay, Chris
    Madan, Rashna
    Pessetto, Ziyan Y.
    Godwin, Andrew K.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (03)
  • [26] Adverse events (AE) following diagnosis (Dx) in older metastatic colorectal cancer (mCRC) patients (Pts)
    Shankaran, Veena
    Mummy, David G.
    Blough, David K.
    Koepl, Lisel
    Yim, Yeun Mi
    Yu, Elaine
    Ramsey, Scott David
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [27] Clinical benefit from bevacizumab (BV) in responding (R) and non-responding (NR) patients (pts) with metastatic colorectal cancer (mCRC).
    Mass, RD
    Sarkar, S
    Holden, SN
    Hurwitz, H
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 249S - 249S
  • [28] Survival impact of primary tumor resection in patients (pts) with unresectable metastatic colorectal cancer (mCRC): Findings from the South Australian Metastatic Colorectal Cancer Registry (SAMCRC).
    Vatandoust, Sina
    Roy, Amitesh Chandra
    Price, Timothy Jay
    Ullah, Shahid
    Beeke, Carol
    Townsend, Amanda Rose
    Padbury, Rob
    Roder, David
    Maddern, Guy
    Karapetis, Christos Stelios
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [29] Observational cohort study focused on treatment continuity of patients (pts) treated with XELOX plus bevacizumab (BV) for previously untreated metastatic colorectal cancer (mCRC).
    Kotaka, Masahito
    Ikeda, Husao
    Ikumoto, Taro
    Tsuzie, Masaki
    Yoshioka, Shinichi
    Nakamoto, Yoshihiko
    Ishii, Takaaki
    Goto, Saori
    Itami, Atsushi
    Kato, Takeshi
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (03)
  • [30] Pharmacogenetic study in patients (pts) with metastatic breast (MBC) and colorectal cancer (MCRC) treated with capecitabine (C)
    Alba, E.
    Ribelles, N.
    Sanchez, A.
    Lopez Siles, J.
    Sanchez, M. J.
    Gonzalez, E.
    Carabantes, F.
    Sanchez Rovira, P.
    Marquez, A.
    Sevilla, I.
    EJC SUPPLEMENTS, 2005, 3 (02): : 66 - 66
12345